Global Ulcerative Colitis Market Analysis & Industry Forecast 2017-2023, With an Expected CAGR of 6.5% - ResearchAndMarkets.com
DUBLIN--(BUSINESS WIRE)--Jun 6, 2018--The “Ulcerative Colitis Market by Molecule Type - Global Opportunity Analysis and Industry Forecast, 2017-2023” report has been added to ResearchAndMarkets.com’s offering.
The global ulcerative colitis market accounted for $4,785 million in 2016 and is expected to reach $7,455 million by 2023, registering a CAGR of 6.5% from 2017 to 2023.
Ulcerative colitis (UC) is an inflammatory gastrointestinal disease that affects colon or large intestine. UC is characterized as an incurable disease with low mortality rate and is generally diagnosed in adolescence and early adulthood. As per NCBI, about 1.86 billion patients were diagnosed with UC globally in 2014, with 1.54 billion patients currently receiving treatment.
The major factors that drive the growth of the global ulcerative colitis market are increasing number of ulcerative colitis patients, new drug formulations by key players, and increasing investments by government and non-government organizations towards research in biologics. However, patent expiry and availability of alternative surgery option for UC treatment restricts the market growth.
The report segments the global ulcerative colitis market based on disease type, molecule type, and route of administration. Based on molecule type, the market is categorized as biologics and small molecules. In terms of disease type, the market is divided into mild, moderate, and severe ulcerative colitis. Based on route of administration, the market is bifurcated into oral and injectables.
Key Topics Covered:
Chapter 1. Introduction
Chapter 2. Executive Summary
Chapter 3. Market Overview
Chapter 4. Ulcerative Colitis, By Disease Type
Chapter 5. Ulcerative Colitis Market, By Molecule Type
Chapter 6. Ulcerative Colitis Market, By Route Of Administration
Chapter 7. Ulcerative Colitis Market, By Geography
Chapter 8. Company Profiles
For more information about this report visit https://www.researchandmarkets.com/research/bpsmnz/global_ulcerative?w=4
View source version on businesswire.com:https://www.businesswire.com/news/home/20180606005525/en/
Laura Wood, Senior Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics:Immune Disorders Drugs,Gastrointestinal Drugs
INDUSTRY KEYWORD: HEALTH PHARMACEUTICAL
SOURCE: Research and Markets
Copyright Business Wire 2018.
PUB: 06/06/2018 05:21 AM/DISC: 06/06/2018 05:21 AM